Get the Stockscreener App
9.59
0.74%
0.07
Amicus Therapeutics Inc stock is traded at $9.59, with a volume of 1.90M.
It is up +0.74% in the last 24 hours and down -19.41% over the past month.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$9.52
Open:
$9.49
24h Volume:
1.90M
Relative Volume:
0.81
Market Cap:
$2.84B
Revenue:
$455.66M
Net Income/Loss:
$-119.54M
P/E Ratio:
-14.98
EPS:
-0.64
Net Cash Flow:
$-48.10M
1W Performance:
-7.52%
1M Performance:
-19.41%
6M Performance:
-1.64%
1Y Performance:
-13.13%
1-Day Range:
$9.38
$9.68
1-Week Range:
$9.37
$10.43
52-Week Range:
$9.02
$14.57
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| FOLD | 9.59 | 2.84B | 455.66M | -119.54M | -48.10M | -0.64 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap DownShould You Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc - GuruFocus.com
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amic - GuruFocus.com
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated - MSN
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc - GuruFocus.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLP - MarketBeat
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics - Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts - Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) - Benzinga
Amicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $17.00 - MarketBeat
FOLDAmicus Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden - Simply Wall St
Fiera Capital Corp Reduces Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Amicu - GuruFocus.com
Amicus Therapeutics CEO Campbell sells $98,800 in stock - Investing.com India
Amicus Therapeutics CEO Campbell sells $98,800 in stock By Investing.com - Investing.com Australia
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Downgraded by StockNews.com to Hold - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Guggenheim - MarketBeat
Teva’s Galafold generic for Fabry disease may be available in US - Fabry Disease News
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock - Yahoo Finance
Needham & Company LLC Reiterates Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Call Transcript - Insider Monkey
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights - Benzinga
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings - Yahoo Finance
Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance - Investing.com India
Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance By Investing.com - Investing.com Canada
Amicus Therapeutics Q3 2024 Earnings Preview - MSN
Old West Investment Management LLC Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings: Revenue Surges - GuruFocus.com
Amicus Therapeutics: Q3 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - MSN
Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World
Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Cradle of Cures - Site Selection Magazine
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat
abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):